Kornimate/medical-research-clean huggingface dataset:
effect of iranian traditional medicine remedy on chemotherapy induced nausea and vomiting

Conditions: Nausea; Vomiting

Summary: the main objective of this research is the role of the persumac(an iranian traditional remedy) on refractory chemotherapy induced nausea and vomiting (cinv) in breast cancer patients. investigators assess effect of persumac on the number/severity of nausea/ vomiting in acute and delayed phase.

the study was a double-blind, placebo controlled, cross-over clinical trial of iranian traditional remedy (persumac) on chemotherapy induced nausea and vomiting in breast cancer patients. from october 2015 to may 2016, sample selection continued to be until the full sample size. executive steps of study: 1. among patients referred for breast cancer, to the oncology clinic in imam reza hospital in mashhad university of medical sciences, an oncology referral center in the north east of iran; patients included in study who had at least one chemotherapy session and remain at least three sessions of their chemotherapy cycle and had inclusion criteria. 2. the initial assessment of patients (run- in): concurrent with the visit of patient for chemotherapy (the first session of her/his chemotherapy in this study); during interview, study questionnaire was delivered to patient. it took a full explanation of how to complete it and return the next session. 3. in the second session of chemotherapy (in study); after eligibility qualification and obtaining consent form, patients randomly allocated into intervention and control groups, in accordance with the study protocol, interventions take place. questionnaire was delivered to the patient again. 4. (wash out): sixth day after the second session of chemotherapy until a day before the third session of chemotherapy determined as wash out period. 5. in the third session of chemotherapy-in study, after obtaining the previous questionnaire, patient received cross over interventions. questionnaire delivered to the patient again.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of breast cancer, * clinical diagnosis of chemotherapy induced nausea and vomiting resistant to conventional therapy. exclusion criteria: * clinical diagnosis of hypersensitivity to sumac or bunium persicum, * clinical diagnosis of digestion disorders, * clinical diagnosis of non chemotherapy induced nausea and vomiting, * milk allergy, * clinical diagnosis of bleeding diathesis, * clinical diagnosis of non-breast cancer.

Keywords: breast cancer traditional medicine chemotherapy induced nausea and vomiting bunium persicum rhus coriaria
cerebral and peripheral perfusion pilot study

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to evaluate the hypothesis that in middle-aged, asymptomatic, adult children of persons with alzheimer's disease (ad), atorvastatin therapy will beneficially affect mechanisms thought to contribute to ad risk by improving blood flow in the brain, improving cerebral perfusion, increasing brain activity patterns, and improving blood vessel function.

treatment with cholesterol-lowering medications, specifically statins, is associated with up to a 73% reduction in the prevalence of ad, suggesting a potentially promising role for statins in the prevention of ad. in order to better understand the mechanisms through which statins may possibly modify blood ad risk, this study evaluated whether administration of atorvastatin favorably altered blood flow in the brain (measured by magnetic resonance imaging (mri)) and blood vessel function (measured by ultrasound). participants attended 3 visits over the course of the 4-month study. at the initial visit, participants completed a short questionnaire about their past medical history and medication history. at the baseline visit, participants were randomized in a 1:1 ratio to receive atorvastatin 40 mg nightly vs. matching placebo. at baseline and follow-up visits, participants provided an update on medical problems and medications, reviewed any potential side effects, and had fasting blood tests collected for safety monitoring, including liver and muscle enzyme monitoring. in addition, all participants had mri and ultrasound measures collected.

Eligibility criteria:
inclusion criteria: * adult (ages 40-65) children of parent with documented alzheimer's disease exclusion criteria: * current use of cholesterol lowering medication * history of liver disease * history of adverse reaction to statin medications * elevated lab values (ck and creatinine) * use of medications that counteract with atorvastatin * history of dementia * currently pregnant * use of large quantities of grapefruit juice (more than 1 quart/day) * current involvement in another investigational drug study * contraindications to mri

Keywords: cerebral blood flow
a peer e-mentoring intervention to improve employment

Conditions: Cerebral Palsy; Spina Bifida; Juvenile Arthritis; Spinal Cord Injury; Muscular Dystrophy; Physical Disability

Summary: despite the strong business case of hiring people with disabilities, a significant proportion of youth with disabilities leave high school and neither work nor continue their education and are unprepared to meet the demands of a work environment. although youth with disabilities have much to gain from employment readiness programs, they are often excluded from, or have limited access to school and community vocational programs. one encouraging approach to address gaps in vocational programming is through peer mentoring, which may facilitate a smoother transition to adulthood by offering support to enhance coping skills. despite the increase in online communities, little is known about their impact on vocational mentoring for youth with physical disabilities and their parents. the purpose of this study is to develop, implement and assess the feasibility of an online peer mentor employment readiness intervention for youth with physical disabilities and their parents to improve their self-efficacy, career maturity and social support.

our primary objective is: (1) to develop, implement and assess the feasibility of an online peer mentor employment readiness intervention for youth with physical disabilities and their parents to improve their self-efficacy, career maturity and social support. a mixed methods feasibility randomized controlled trial design will be conducted to develop and assess the usability of "empowering youth towards employment" intervention. youth (aged 15-25) with physical disabilities and their parents will be randomly assigned to a control or experimental group (12-week, interactive intervention, moderated by peer mentors). a qualitative thematic analysis will be conducted to analyze the content of discussion forums. interviews with youth, parents and mentors will also be conducted about their experiences in the intervention.

Eligibility criteria:
inclusion criteria for youth participants: * able to read/write in english; * a diagnosed physical disability (i.e., cerebral palsy, muscular dystrophy, spinal cord injury etc.); (4) currently enrolled in or have completed a high school diploma in the applied / academic stream (to screen for cognitive impairment); * aged 15-25; * have access to a computer and internet; * have no paid work experience. inclusion criteria for parents: * are the parent of a youth meeting above inclusion criteria * can read/write in english * have access to a computer with internet exclusion criteria: * recently completed or currently participating in another employment readiness or peer support intervention.
efficacy and safety of oral isotretinoin for cutaneous photodamage

Conditions: Photodamage; Photoaging

Summary: this is a randomized, comparative, single evaluator-blinded trial to evaluate clinical, histological and immunohistochemical effects of oral isotretinoin plus moisturizer sunscreen as compared to the use of 0,05% tretinoin cream plus moisturizer sunscreen for the treatment of photodamage on face and forearms. main oral isotretinoin safety parameters will also be analyzed, as well as adverse events related to topical products.

a 24-week study, with 7 or 9 monthly visits, comprising healthy adult volunteers, aged 50 to 75 years will be carried out. the patients should present advanced to severe photodamage on face and forearms. written informed consent will be obtained from each subject prior to enrollment. eligible patients will be randomly divided in two groups: a- 10 patients will be treated with oral isotretinoin, 20.0 mg/day, every other day, 15 capsules per month, for 24 weeks, associated with the use of moisturizer broad spectrum sunscreen twice a day. b- 10 patients (controls) will be treated with 0,05% tretinoin cream applied on face and forearms at night and the same moisturizer broad-spectrum sunscreen twice a day. after randomization, laboratory tests will be requested for patients from group a and will be repeated on weeks 4 and 24.

Eligibility criteria:
inclusion criteria: * patients aged from 50 to 75 years old * post-menopausal women for at least one year * patients with moderate to severe photodamage on face and arms * individuals in generally good health * fitzpatrick i to iii skin type * patients who are willing to avoid sun-exposure during the study period exclusion criteria: * patients of child bearing potential * individuals who have been treated with topical anti-aging products and/or superficial chemical peels within 3 months or received topical tretinoin or oral retinoid (6 months); fillers and/or botulinum toxin applications (4 months); medium-depth chemical peels or ablative lasers or dermabrasion (6 months) and surgical lifting (12 months) will not be eligible for inclusion in the study * patients on cytotoxic drugs (including azathioprine, cyclophosphamide, mycophenolate mofetil, or other chemotherapeutic agents) within 3 months * hypersensitivity to parabens * an infectious or inflammatory dermatosis of the face, scalp or forearms including acne rosacea * a history of photodermatosis (example pmle) * immunocompromised individuals * patients with auto-immune diseases * patients addicted to drugs or alcohol

Keywords: brazil isotretinoin photodamage photoaging
phase 4 study to demonstrate prognostic usefulness of adreview™ scintigraphy for identifying subjects with heart failure who will experience death during 60 months follow-up.

Conditions: Heart Failure (HF)

Summary: this aim of the study is to investigate the prognostic usefulness of adreview™ imaging to identify those subjects with new york heart association (nyha) class ii or iii hf who will die during 60 months of follow-up from the date of administration of adreview™ in prior studies mbg311, mbg312, or mbg312c (hereafter included in mbg312).


Eligibility criteria:
inclusion criteria: * the subject was a hf subject who had signed informed consent for mbg311 or mbg312. * the subject was administered adreview™ in mbg311 or mbg312. * the subject completed the late planar imaging assessments (at a minimum) required by the protocols for mbg311 and mbg312, and those images were read and judged diagnostic by at least 2 blinded readers. * in addition, all subjects must meet 1 of the following 3 inclusion criteria. * if the subject can be located, he/she provides informed consent to allow the investigator access to medical records and/or gives permission for the investigator to speak to treating physicians. * if the subject can be located and he/she declines to provide informed consent, the irb/ec provides a waiver of consent to allow the investigator to record that the subject is alive. * if the subject cannot be located, the irb/ec provides a waiver of consent to allow the investigator to access available medical records for care provided subsequent to last date of subject participation in mbg311, mbg312, and/or mbg313 and/or to allow collection of data from publicly available sources. exclusion criteria: * the subject withdrew or was withdrawn from mbg311 or mbg312 because of a protocol violation. * the subject underwent heart transplantation during mbg311, mbg312, or mbg313. * the subject was recorded to have died during mbg311, mbg312, or mbg313. * the subject voluntarily withdrew from mbg311, mbg312, or mbg313, and the irb/ec has not provided a waiver to allow recording of subject survival status in such an instance. * the subject cannot be located, cannot be contacted, and no information can be found to establish survival status beyond the date of last contact in mbg311, mbg312, or mbg313, including information available as a result of an irb/ec-approved waiver.

Keywords: myocardial sympathetic innervation heart failure (hf) nuclear imaging radiopharmaceutical
reduction of allogenic blood transfusion in locally advanced kidney cancer

Conditions: Kidney Cancer

Summary: the reduction of allogenic blood transfusion in locally advanced kidney cancer trial (restrict). the primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ ct2). secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

the reduction of allogenic blood transfusion in locally advanced kidney cancer trial (restrict) is a randomized study to investigate blood sparing using autologous normovolemic hemodilution (anh) or cell salvage at the time of nephrectomy for locally advanced kidney cancer after assessing inclusion criteria patients will be randomized to undergo standard blood management including the possibility of allogenic transfusion vs autologous blood transfusion. there are multiple ways patients can receive allogenic or autologous blood, including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with a thrombus above the level of the hepatic veins or entering the heart).

Eligibility criteria:
inclusion criteria: * renal masses ≥ ct2 (by any conventional imaging). * n1 or m1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy). * male and female patients. * 18 and older. * ejection fraction (ef) ≥ 45% by echocardiogram (echo). * adequate organ function as defined by: * hemoglobin ≥ 9 g/dl. pre-operative allogenic blood transfusion is allowed. * platelets ≥ 100.000/μl. * albumin ≥ 2.5 g/dl. * aspartate aminotransferase (ast) and alanine transaminase (alt) ≤ 75u/l or total bilirubin ≤ 2.0 mg/dl. * wbc within institutional normal limits. * pt within institutional normal limits. * inr \< 1.5 and ptt normal. * consent and compliance with all aspects of the study protocol. exclusion criteria: * male and female younger than 18 years old. * non-surgical candidate * unstable angina.

Keywords: nephrectomy blood sparing allogenic blood transfusion
correlation between suv on 68ga-hbed-cc-psma and gleason score in prostate cancer

Conditions: Prostate Cancer

Summary: prostate cancer is the second leading cause of cancer death in north american men older than 50 years. prostate specific membrane antigen (psma) is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer. positron emission tomography / computer tomography (pet/ct) is a nuclear medicine procedure based on the measurement of positron emission from radiolabeled tracer molecules. 68ga-hbed-cc-psma (dkfz-11) (abbreviated 68ga-psma) is a tracer for prostate cancer pet imaging. the strength of functional imaging methods is in distinguishing tissues according to metabolism rather than structure. studies have shown that pet/ct imaging with 68ga-psma can detect prostate cancer lesions with excellent contrast and a high detection rate even when the level of prostate specific antigen is low. study objectives: the objective of this study is to evaluate if the patient-wide suvmax on 68ga-psma pet/ct in locoregional and metastatic prostate cancer correlates with histopathologic gleason score at initial biopsy. it is hypothesized that suvmax will correlate positively with gleason score. this is of interest because non-invasive risk stratification may be possible in the future. this will be a single-site jgh-only open label study in which one (1) 68ga-psma pet/ct will be performed on study participants. a pet/ct scan takes 2-3 hours.


Eligibility criteria:
inclusion criteria: * resident of canada * male sex * age 18 years or older * previous diagnosis of prostate cancer with gleason score available * ecog performance status 0 - 3, inclusive * able to understand and provide written informed consent * referred by a treating physician * able to tolerate the physical/logistical requirements of a pet/ct scan including lying supine for up to 45 minutes with the arms above the head and tolerating intravenous cannulation for injection of the study drug exclusion criteria: * medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.) * patients who exceed the safe weight limit of the pet/ct bed (200 kg) or who cannot fit through the pet/ct bore (70 cm diameter) * patients who are claustrophobic
cryotherapy in breast b3 lesions

Conditions: Breast Disease; Phyllodes Breast Tumor

Summary: to determine the feasibility of cryotherapy for b3 fibroepithelial lesions


Eligibility criteria:
inclusion criteria: * lesion seen on ultrasound * core biopsy revealed fel of b3 * lesion \</+3.5cm * keen for cryotherapy instead of surgery * has other breast lesions for followup exclusion criteria: * cancer patients * patients with bleeding diathesis * lesions causing visible breast deformity
network-based approach in type 2 diabetes and its cardiovascular risk

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Diseases

Summary: piramide study design will test the hypothesis that simultaneous interactions between dna methylation and micrornas may hit t2d candidate genes and predict the development of t2d-related cardiovascular complications.


Eligibility criteria:
exclusion criteria: * clinical diagnosis of type 2 diabetes. in according to current guidelines, diabetes is diagnosed by evidence of impairing fast glucose (ifg) \> 7.0 mmol/l (\>125 mg/dl), post prandial glycemia \> 11.1 mmol/l (\>200 mg/dl), and evidence of glycated hemoglobin (hba1c) \> 6.6%. clinical and demographic characteristics of study population will be avaiable from datasets generated by physicians. * clinical diagnosis of macrovascular dysfunction. exclusion criteria: • patients with known history of cancer, malignancy disorders, active infections, and chronic or immune-mediated diseases.

Keywords: network medicine epigenetics diabetes cardiovascular risk
lactoferrin prophylaxis in vlbw and regulator t-cells

Conditions: Late Onset Neonatal Sepsis; Necrotising Enterocolitis; Very Low Birth Weight Infants

Summary: the aim of the study is to evaluate whether oral administration of 200 mg/day lactoferrin (lf) to very low birth weight infants reduces late onset sepsis and necrotising enterocolitis and the effect of lf on regulatory t cells.


Eligibility criteria:
inclusion criteria: * inborn infants * gestational age \< 32 weeks * birth weight \< 1500 g * parental consent exclusion criteria: * congenital abnormalities * severe perinatal asphyxia

Keywords: vlbw, nec, late onset sepsis
omega 3 oil: aging-related cognitive decline

Conditions: Aging Related Cognitive Decline

Summary: aging-related cognitive decline may be affected by brain cholesterol and the health of cell membranes. certain nutritional supplements have been proposed to support membrane health, and there is increasing interest in plasmalogens and omega-3 derived oil supplements to support brain health among older adults. plasmalogens are compounds found in neural cell membranes that are connected to cholesterol processing. neural cells that have low plasmalogens have shown an inability to process cholesterol properly. recent research suggests that abnormalities in cholesterol processing and low levels of plasmalogen may play a role in age-related cognitive decline. the product being investigated in this study is the prodromeneuro omega 3 oil nutritional supplement. this product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. the purpose of this research study is to better understand the effects of prodromeneuro omega-3 nutritional supplementation among participants with age-related cognitive decline. it is hoped that taking this product over the course of 4 months will result in improved plasmalogen levels, brain connectivity seen on advanced brain imaging, as well as improved cognitive assessment measurements.


Eligibility criteria:
inclusion criteria: * evidence of a degenerative process * clinical dementia rating (cdr) score indicating mild cognitive impairment (cdr = 0.5), mild dementia (cdr = 1) through moderate dementia (cdr = 2) exclusion criteria: * subjects unable to give informed assent * cognitive decline clearly related to an acute illness * advanced terminal illness * any active cancer or chemotherapy * any other neoplastic illness or illness characterized by neovascularity or angiopathy * subjects previously taking plasmalogen supplementation prior to study enrollment
efficacy of selective laser trabeculoplasty in pseudophakic patients

Conditions: Glaucoma; Ocular Hypertension

Summary: retrospective analysis of efficacy of selective laser trabeculoplasty in pseudophakic patients compared to phakic patients is performed. inclusion criterion are patients with glaucoma or ocular hypertension who underwent treatment with selective laser trabeculoplasty due to insufficient control of intraocular pressure during their routine treatment at the university hospital zurich / division of ophthalmology.


Eligibility criteria:
inclusion criteria: * patients with glaucoma or ocular hypertension who underwent selective laser trabeculoplasty. exclusion criteria: * optic neuropathy other than glaucoma

Keywords: patients with glaucoma or ocular hypertension